In this introductory paper on radionuclide adrenal imaging, the rationale, synthesis, formulation, and metabolism of two clinically well-established and one promisinmg adrenocortical imaging agents are reviewed. Their present clinical utility is reviewed in a separate presentation in this issue. Progress to date in developing a positive imaging agent of the adrenal medulla and tumors of chromaffin tissue will be given brief consideration because there is, as yet, no clinically successful radiolabeled adrenal medulla imaging agent.